Free shipping on all orders over $ 500

ON123300

Cat. No. M7557
ON123300  Structure
Synonym:

Narazaciclib

Size Price Availability Quantity
5mg USD 140  USD140 In stock
10mg USD 210  USD210 In stock
25mg USD 420  USD420 In stock
50mg USD 780  USD780 In stock
100mg USD 1120  USD1120 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: ON123300 is a novel kinase inhibitor, inhibits CDK4/6 and PI3K-δ and exhibits potent activity against mantle cell lymphomas (MCLs). ON123300 is a low molecular weight multi-kinase inhibitor identified through a series of screens that supported further analyses for brain tumor chemotherapy. Biochemical assays indicated ON123300 was a strong inhibitor of Ark5 and CDK4 as well as growth factor receptor tyrosine kinases such as Beta-type platelet-derived growth factor receptor [PDGFRβ]. ON123300 inhibited U87 glioma cell proliferation with an IC50 = 3.4 ± 0.1 μM and reduced phosphorylation of Akt, yet it also unexpectedly induced Erk activation; both in a dose- and time-dependent manner that subsequently was attributed to relieving Akt-mediated C-Raf S259 inactivation and activating a p70S6K initiated PI3K negative feedback loop.

Protocol (for reference only)
Cell Experiment
Cell lines MM1.S and NCI-H929 cells
Preparation method MM1.S and NCI-H929 cells were treated with ON123300/PD-0332991 for 24 hours. Approximately 106 cells of each cell line were harvested (along with untreated controls) after 24 hours of treatment in 12-well plates. Cells were washed with PBS and resuspended in appropriate volume of Annexin binding buffer and then stained with Annexin V Pacific Blue/PI.
Concentrations 50 nmol/L
Incubation time 24 h
Animal Experiment
Animal models
Formulation
Dosages
Administration
Chemical Information
Molecular Weight 429.52
Formula C24H27N7O
CAS Number 1357470-29-1
Solubility (25°C) 10 mM in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Perumal D, et al. Cancer Res. Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.

[2] Divakar SK, et al. Leukemia. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.

Related CDK Products
PF-07224826

PF-07224826 is a CDK2/4/6 inhibitor.

INCB123667

INCB123667 is a CDK2 inhibitor.

Senexin B

Senexin B is a potent, orally active CDK8/19 inhibitor with Kd values of 140 nM and 80 nM for CDK8 and CDK19, respectively.

Q901

Q901 is a CDK7 inhibitor for tumor-related studies.

NUV-422

NUV-422 is a CDK2/4/6 inhibitor that can be used in studies related to malignant gliomas.

  Catalog
Abmole Inhibitor Catalog




Keywords: ON123300 , Narazaciclib supplier, CDK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.